Clinical implication of endothelial dysfunction in patients with essential arterial hypertension and urate dysbolism with renal damage


Cite item

Full Text

Abstract

Aim. To study correlations between severity of hyperuricemia, endothelial dysfunction (ED) and arterial atherosclerosis (AS).
Material and methods. A total of 50 patients with essential hypertension of degree I-II free of associated clinical conditions entered the trial. The study group consisted of 40 patients with hyperuricemia, the control group - of 10 patients with normal blood serum levels of uric acid.
Results. The study group patients versus controls had significantly higher albuminuria (93.5±1.7 and 60.7±2.2 mg/l; p < 0.001), plasmic concentration of endotheline-1 (6.8±0.3 and 4.9±0.2 pg/ml; p < 0.001)and thickness of the intima-media complex of the common carotid artery (1.36±0.02 and 1.1±0.04; p < 0.001). All the indices correlated directly and significantly.
Conclusion. Patients with arterial hypertension of the first-second degree with persistent elevated levels of uric acid in blood serum had significantly higher levels of ED markers: albuminuria, plasmic endothelin concentration. Hyperuricemia and ED in such patients lead to more active progression of atherosclerotic vascular lesion.

About the authors

Tat'yana Yur'evna Stakhova

Email: tstakhova@mail.ru

Andrey Alekseevich Pulin

Email: andreypulin@gmail.com

Mariya Mikhaylovna Severova

Email: mseverova@mail.ru

Tat'yana Nikolaevna Shovskaya

Email: knvpb@mma.ru

Elena Germanovna Minakova

Email: knvpb@mma.ru

Elena Borisovna Oleynikova

Email: knvpb@mma.ru

Marina Valer'evna Lebedeva

Email: marinaamica@mail.ru

T Yu Stakhova

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

A A Pulin

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

M M Severova

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

T N Shovskaya

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

E G Minakova

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

E B Oleinikova

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

M V Lebedeva

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

References

  1. Шальнова С. А., Деев А. Д., Оганов Р. Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваск. терапия и профилактика 2005; 1: 3-8.
  2. Российское медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр). М.; 2008.
  3. ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J. Hypertens. 2007; 21: 1011-1053.
  4. Fang J., Alderman M. H. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA, 2000; 283: 2404-2410.
  5. Culleton B. F., Larson M. G., Kannel W. B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med. 1999;131:7-13.
  6. Baker J. F., Krishnan E., Chen L., Schumacher H. R. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am. J. Med. 2005; 118: 816-826.
  7. Bos M. J., Koudstaal P. J., Hofman A. et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study. Stroke 2006; 37: 1503-1507.
  8. Kim S. Y., Guevara J. P., Kim K. M. et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthr. and Rheum. 2009; 61: 885-892.
  9. Kanellis J., Kang D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 2005; 25: 39-42.
  10. Feig D. I., Kang D. H., Johnson R. J. Uric acid and cardiovascular risk. N. Engl. Med. 2008; 359: 1811-1821.
  11. Mazzali M., Kanellis J., Han L. et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal Physiol. 2002; 282: F991-F997.
  12. Mazzali M., Hughes J., Kim Y. G. et al. Elevated uric acid increases blood pressure in rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
  13. Khosla U. M., Zharikov S., Finch J. L. et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739- 1742.
  14. Sanchez-Lozada L. G., Tapia E., Lopez-Molina R. et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J. Physiol. Renal Physiol. 2007; 292: F1238- F1244.
  15. Landmesser U., Drexler H. The clinical significance of endotelial dysfunction. Curr. Opin. Cardiol. 2005; 20(6): 547-551.
  16. Johnson R. J., Kang D. H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
  17. Сагинова E. A., Фомин B. B., Моисеев С. В. и др. Поражение почек при ожирении. Тер. арх. 2007; 6: 88-94.
  18. Mazzone Т. Adipose tissue and the vessel wall. Curr. Drug Targets 2007; 8(11): 1190-1195.
  19. Балахонова T. B. Ультразвуковая диагностика атеросклероза. B кн.: Чазов Е. И. (ред.). Руководство по атеросклерозу и ишемической болезни сердца. М.: Медиа Медика; 2007.
  20. Ishizaka N., Ishizaka Y., Toda E. I. et al. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1038-1044.
  21. Ishizaka N., Ishizaka Y., Toda E. I. et al. Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis 2007; 192(1): 131-137.
  22. Kawamoto R., Tomita H., Oka Y., Ohtsuka N. Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intern. Med. 2006; 45: 605-614.
  23. Iribarren C., Folsom A. R., Eckfeldt J. H. et al. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities. Ann. Epidemiol. 1996; 6: 331-340.
  24. Бритов A. H. Оценка сердечно-сосудистого риска при ведении больных артериальной гипертонией. Кардиоваск. тер. и профилакт. 2003; 3: 9-17.
  25. Шоничев Д. А., Балкаров И. М., Лебедева М. В. и др. АГ у лиц с нарушением обмена мочевой кислоты. Тер. аpx. 1999; 6: 17-20.
  26. Kanellis J., Kang D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 2005; 25: 39-42.
  27. Мухин H. A., Моисеев B. C., Кобалава Ж. Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. арх. 2004; 6: 39-46.
  28. Мухин Н. А., Фомин В. В., Моисеев С. В. и др. Микроальбуминурия - интегральный маркер кардиоренальных взаимоотношений при артериальной гипертонии. Consilium Medicum 2007; 9(5): 13-18.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies